FAMAR has announced the closing of the acquisition of the sterile production site from MiP Pharma, located in Homburg, Germany.
Full ownership of the site, as well as approximately 100 employees, will be transferred to Famar.
The closing of the acquisition means that Famar will regain a presence in Northern Europe, strengthening its footprint in high-value dosage forms and expanding its capabilities in aseptic and lyophilised fill & finish.
The CDMO also has seven other sites located elsewhere in Europe, all offering flexible, high-quality and scalable production solutions.
The new Homburg site will be operated by Famar Healthcare Germany GmbH.
Konstantinos Rengis, CEO of FAMAR Group, said: “This acquisition is an important step for Famar, as it aligns with our strategy to grow in differentiated dosage forms and expand our capacity to support global customers with manufacturing services of the highest standards."
"It allows Famar to strengthen its footprint in Europe, expanding its network into Germany, one of the most respected pharmaceutical markets in the world. We are proud to welcome the Homburg team to the FAMAR family and look forward to building a strong future together."
Matthew Strassberg, Partner and Head of Healthcare at MidEuropa, commented: “This deal highlights our conviction in FAMAR’s strategy and our capability to support international expansion of our portfolio companies."
"By providing substantial new equity, we are ensuring that FAMAR has the resources needed to serve its global customer base and accelerate its long-term growth."